ATE154245T1 - Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen - Google Patents

Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen

Info

Publication number
ATE154245T1
ATE154245T1 AT91907581T AT91907581T ATE154245T1 AT E154245 T1 ATE154245 T1 AT E154245T1 AT 91907581 T AT91907581 T AT 91907581T AT 91907581 T AT91907581 T AT 91907581T AT E154245 T1 ATE154245 T1 AT E154245T1
Authority
AT
Austria
Prior art keywords
cell growth
combinations
combination
individually
inhibiting cell
Prior art date
Application number
AT91907581T
Other languages
English (en)
Inventor
Ian Stuart Trowbridge
Raymond Taetle
Suhaila Nakhoul White
Original Assignee
Salk Inst For Biological Studi
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi, Univ California filed Critical Salk Inst For Biological Studi
Application granted granted Critical
Publication of ATE154245T1 publication Critical patent/ATE154245T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
AT91907581T 1990-03-27 1991-03-26 Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen ATE154245T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50003590A 1990-03-27 1990-03-27

Publications (1)

Publication Number Publication Date
ATE154245T1 true ATE154245T1 (de) 1997-06-15

Family

ID=23987769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91907581T ATE154245T1 (de) 1990-03-27 1991-03-26 Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen

Country Status (8)

Country Link
US (1) US5667781A (de)
EP (1) EP0525005B1 (de)
JP (1) JPH05505823A (de)
AT (1) ATE154245T1 (de)
AU (1) AU642014B2 (de)
CA (1) CA2081368A1 (de)
DE (1) DE69126526T2 (de)
WO (1) WO1991014452A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159330C (en) * 1993-05-03 2004-06-15 Laurence A. Lasky Inhibition of leukocyte adhesion
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
EP1620564A4 (de) * 2003-04-18 2008-03-12 Cytovia Inc Verfahren zur behandlung von auf apoptoseinduktion reagierenden krankheiten und screening-tests
US6977720B2 (en) * 2003-08-05 2005-12-20 Agilent Technologies, Inc. Characterization of active and passive optical properties of an optical device
US20060029597A1 (en) * 2004-03-31 2006-02-09 Chimeric Technologies IgA antibody protein as a cytotoxic drug
ATE537189T1 (de) 2004-04-30 2011-12-15 Inst Nat Sante Rech Med Anti-tfr-antikörper
CA2569692C (en) * 2004-06-07 2015-07-21 Raven Biotechnologies, Inc. Transferrin receptor antibodies
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
US9267952B2 (en) 2008-11-05 2016-02-23 Morphosys Ag Deconvolution method
WO2010089782A1 (en) * 2009-02-05 2010-08-12 Saverio Alberti Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
CA2766272C (en) 2009-06-26 2021-02-09 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
WO2011130164A2 (en) * 2010-04-13 2011-10-20 The Regents Of The University Of California Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
NZ724348A (en) 2010-11-30 2019-12-20 Genentech Inc Low affinity blood brain barrier receptor antibodies and uses therefor
JP5980202B2 (ja) 2011-05-09 2016-08-31 株式会社ペルセウスプロテオミクス トランスフェリン受容体を特異的に認識できる抗体
CN102827813B (zh) * 2012-09-30 2014-12-31 苏州大学 抗人cd133单克隆抗体及其制备和应用
PT2918603T (pt) 2012-11-08 2018-10-30 Univ Miyazaki Anticorpo capaz de reconhecer especificamente o receptor da transferrina
US9499628B2 (en) * 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
JP2018024615A (ja) * 2016-08-10 2018-02-15 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物
WO2023015234A1 (en) * 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US11827702B2 (en) 2021-09-01 2023-11-28 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4925922A (en) * 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates

Also Published As

Publication number Publication date
AU642014B2 (en) 1993-10-07
AU7667091A (en) 1991-10-21
DE69126526T2 (de) 1998-02-05
EP0525005A1 (de) 1993-02-03
DE69126526D1 (de) 1997-07-17
CA2081368A1 (en) 1991-09-28
WO1991014452A1 (en) 1991-10-03
US5667781A (en) 1997-09-16
JPH05505823A (ja) 1993-08-26
EP0525005B1 (de) 1997-06-11
EP0525005A4 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
ATE154245T1 (de) Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen
ATE124421T1 (de) Verfahren zur wachstumshemmung von stammzellen.
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
DK0627002T3 (da) Kloning og ekspression af humaniserede monoklonale antistoffer mod human interleukin-4
PT888349E (pt) Pirrolopirimidinas e processos para a sua preparacao
DE3750342T2 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE69713499D1 (de) Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
ATE238800T1 (de) Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe
DK0584082T3 (da) Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
DK0728194T3 (da) In situ modifikation og manipulation af stamceller fra centralnervesystemet.
DK388384A (da) Monoklone antistoffer med specifitet for membran-associerede antigener, deres fremstilling og anvendelse
IS2631B (is) Aðferðir þar sem integrín-mótlyf eru notuð til að meðhöndla margföld mergæxli og uppsog í bein af völdum mergæxla
DE3684211D1 (de)
PT939809E (pt) Ligandos do receptor de tie-2 (ligando 3 de tie e ligando 4 de tie) e suas utilizacoes
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
TR199701013T1 (xx) Nitrik oksit synthas'�n�n inhibit�rleri olarak mercapto ve seleno t�revleri.
DE69535263D1 (de) Angiotensin ii zur verbesserung der befruchtung
NO954781D0 (no) Fremgangsmåter for screening av substanser med en modulerende virkning på en interleukin-5-reseptoravhengig cellulær signaloverföringsvei
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DK0504307T3 (da) Fremgangsmåde til behandling af septisk shock
AU3088984A (en) Antibodies and compositions thereof for inhibiting dental induced by s. abitans
DK24891D0 (da) Monoklonalt antistof til inhibering af cellers infektion med hiv-vira
DE69112392T2 (de) Bcrf1-antagonisten zur behandlung von epstein-barr-virus-infektionen.
ATE89749T1 (de) Verfahren zur bildlichen darstellung von tumoren unter verwendung von monoklonalen antikoerpern.
DE58904518D1 (de) Verfahren zur bildlichen darstellung von tumoren unter verwendung von monoklonalen antikoerpern.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties